BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...payments, which could total up to $290 million.InCarda...
...505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...molecule drug discovery platform targeting the solute carrier (SLC) family of transporters. Cardiovascular disease company InCarda Therapeutics Inc....
...the healthcare and biotech team. Chico was VP of equity research at Raymond James. BioCentury Staff Esteve S.A. InCarda JMP...
BioCentury | Jun 23, 2017
Clinical News

InCarda's inhaled flecainide well tolerated in Phase I

...circulation within 1-3 minutes, "yielding venous plasma levels sufficient to elicit its expected electrophysiological effects." InCarda...
...flecainide. The company plans to start a Phase II trial of the product in 1H18. InCarda Therapeutics Inc....
...AF) Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: Start Phase II (1H18) Julian Zhu inhaled flecainide InRhythm InCarda Therapeutics Inc. Nav1.5...
BioCentury | Sep 5, 2016
Clinical News

Inhaled flecainide: Phase I started

...Phase I trial to evaluate single ascending doses of inhaled flecainide in 38 healthy volunteers. InCarda Therapeutics Inc....
BioCentury | Apr 6, 2016
Company News

Management tracks

...was CFO of ZS Pharma Inc. , which AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired. Cardiovascular company InCarda Therapeutics Inc....
BioCentury | May 4, 2015
Financial News

InCarda completes venture financing

...Type: Venture financing Raised: $5 million Investors: Morningside Venture Investments; and other undisclosed investors Note: InCarda...
Items per page:
1 - 6 of 6
BioCentury | Oct 21, 2020
Deals

Oct. 21 Quick Takes: Clear path for BMS in MyoKardia deal; plus WuXi Biologics rises, Purdue settles, Actemra, Cara-Vifor and more

...payments, which could total up to $290 million.InCarda...
...505(b)(2) pathway. BC Staff OxyContin, oxycodone MyoKardia Inc. Purdue Pharma L.P. Cara Therapeutics InCarda Azitra Zosano Leaps...
BioCentury | Apr 5, 2019
Company News

Management tracks: Zealand taps Alnylam’s Dulac as CEO, plus ICER, Jnana and more

...molecule drug discovery platform targeting the solute carrier (SLC) family of transporters. Cardiovascular disease company InCarda Therapeutics Inc....
...the healthcare and biotech team. Chico was VP of equity research at Raymond James. BioCentury Staff Esteve S.A. InCarda JMP...
BioCentury | Jun 23, 2017
Clinical News

InCarda's inhaled flecainide well tolerated in Phase I

...circulation within 1-3 minutes, "yielding venous plasma levels sufficient to elicit its expected electrophysiological effects." InCarda...
...flecainide. The company plans to start a Phase II trial of the product in 1H18. InCarda Therapeutics Inc....
...AF) Endpoint: Safety and pharmacokinetics Status: Phase I data Milestone: Start Phase II (1H18) Julian Zhu inhaled flecainide InRhythm InCarda Therapeutics Inc. Nav1.5...
BioCentury | Sep 5, 2016
Clinical News

Inhaled flecainide: Phase I started

...Phase I trial to evaluate single ascending doses of inhaled flecainide in 38 healthy volunteers. InCarda Therapeutics Inc....
BioCentury | Apr 6, 2016
Company News

Management tracks

...was CFO of ZS Pharma Inc. , which AstraZeneca plc (LSE:AZN; NYSE:AZN) acquired. Cardiovascular company InCarda Therapeutics Inc....
BioCentury | May 4, 2015
Financial News

InCarda completes venture financing

...Type: Venture financing Raised: $5 million Investors: Morningside Venture Investments; and other undisclosed investors Note: InCarda...
Items per page:
1 - 6 of 6